Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endo’s Generics Face Competitive Pressures

Company Sees Predicted Decline In Overall & Generics Revenues

Executive Summary

After seeing increased demand because of COVID-19 in the first quarter of 2020, Endo’s generics segment has seen a predicted decrease in revenues in the second quarter. Furthermore, the company has also predicted an unfavorable impact due to competitive pressures for 2020 as a whole.

You may also be interested in...

Endo Aims To Stabilize Generics Unit In 2021

Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.

Generics Industry Counts Cost Of Stormy Second Quarter

As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.

Dr Reddy’s Pounces On US Ciprodex Generic As Endo Stumbles

Dr Reddy’s Laboratories has leapfrogged Endo by launching a generic version of of Bayer/Alcon’s Ciprodex (ciprofloxacin/dexamethasone) 0.3%/0.1% otic suspension, as the US firm was stung with a major rejection by the US FDA.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts